{"hq_id":"hq-p-hom-000048","name":"Municipal Tap Water (Pharmaceutical and Hormone Contamination — PPCPs/EDCs)","category":{"primary":"household","secondary":"","tags":[]},"product_tier":"HOM","overall_risk_level":"low","description":"The EPA conducted a national study of pharmaceuticals in streams in 2002. Eighty percent of streams tested contained at least one pharmaceutical.","synthesis":{"derived_risk_level":"low","synthesis_confidence":0.5,"synthesis_method":"compound_composition","context_used":"human_child","context_source":"product_users","exposure_modifier":0.935,"vulnerability_escalated":true,"escalation_reason":"Child exposure group","compounds_resolved":4,"compounds_total":4,"synthesis_date":"2026-05-09","synthesis_version":"1.2.0","methodology_note":"exposure_modifier and adjusted_magnitude are computed from ALETHEIA-calibrated heuristics (route × duration × frequency multipliers, clamped to [0.5, 1.4]). Multipliers are directionally informed by EPA Exposure Factors Handbook (2011) and CalEPA OEHHA but are not regulatory consensus. See /api/methodology for full disclosure."},"hazard_summary":{"critical_concern":"330 million Americans drink municipal water contaminated with pharmaceuticals. No federal MCL for ANY pharmaceutical in drinking water. USGS national tap water study (2022, limited sample) detected ethinyl estradiol in some supplies and carbamazepine in many. Standard drinking water treatment (chlorination, coagulation) does not remove pharmaceuticals at ng/L concentrations. Lifetime chronic sub-therapeutic pharmaceutical exposure for entire population. Unknown human health significance.","key_hazards":["Ethinyl estradiol (birth control pill hormone) — endocrine disruptor; feminizes male fish at 1–5 ng/L; no safe threshold established for humans","Metformin (diabetes drug) — most prevalent; 70–80% US streams; chronic human exposure never risk-assessed","Antibiotics (trimethoprim, erythromycin) — select for antibiotic-resistant gut bacteria; sub-therapeutic drinking water concentrations drive resistance","No federal monitoring mandate — utilities not required to test for pharmaceuticals","No treatment mandate — standard treatment insufficient; reverse osmosis required for removal (not widely adopted)"],"overall_risk":"low","primary_concerns":[],"sensitive_populations":"","exposure_routes":""},"exposure":{"routes":["dermal","inhalation"],"contact_types":["dermal","inhalation"],"users":["adult","child"],"duration":"minutes","frequency":"weekly","scenarios":["Incidental mouthing or hand-to-mouth transfer by children"],"notes":"Exposure to Municipal Tap Water (Pharmaceutical and Hormone Contamination — PPCPs/EDCs) occurs via dermal, inhalation. Children and infants face higher exposure per body weight due to developing detoxification systems, higher surface-area-to-weight ratio, and behavioral factors (mouthing, crawling)."},"consumer_guidance":{"red_flags":[{"indicator":"Identified safety concern","meaning":"330 million Americans drink municipal water contaminated with pharmaceuticals.","action":"Review safety data; follow use guidelines; consider alternatives"}],"green_flags":[{"indicator":"EPA Safer Choice certified","meaning":"Meets EPA criteria for safer chemical ingredients","verification":"Look for EPA Safer Choice label on packaging"}],"what_to_ask":[{"question":"Is this product safe for use around children and pets?","why_it_matters":"Many household chemicals are formulated for adult use; children and pets have higher exposure per body weight and developing organ systems"}],"alternatives":[{"name":"Activated Carbon Filtered Water","notes":"Reduces PPCP/EDC levels through adsorption; improves taste and odor"},{"name":"Reverse Osmosis Treated Water","notes":"Removes broader range of contaminants including some PPCPs and EDCs"}],"notes":null},"regulatory":{"applicable_regulations":[{"jurisdiction":"USA","regulation":"Consumer Product Safety Act (CPSA) + FHSA","citation":null,"requirements":"Household products must not present unreasonable risk of injury. Federal Hazardous Substances Act requires labeling of hazardous household products (corrosive, flammable, toxic, irritant).","compliance_status":null,"effective_date":null,"enforcing_agency":null,"penalties":null,"source_ref":null},{"jurisdiction":"USA","regulation":"EPA Safer Choice / Design for the Environment","citation":null,"requirements":"Voluntary program. Products meeting Safer Choice criteria can display the label. Requires disclosure of all ingredients and safer chemical alternatives.","compliance_status":null,"effective_date":null,"enforcing_agency":null,"penalties":null,"source_ref":null},{"jurisdiction":"EU","regulation":"CLP Regulation (EC) No 1272/2008","citation":null,"requirements":"Classification, labelling, and packaging of hazardous chemical products. GHS-aligned hazard communication. Signal words, pictograms, and precautionary statements required.","compliance_status":null,"effective_date":null,"enforcing_agency":null,"penalties":null,"source_ref":null}],"certifications":[{"name":"CPSC General Safety","issuer":"CPSC","standard":"Consumer Product Safety Act","scope":"General consumer product safety requirements"}],"labeling":{"required_disclosures":[],"prop65_warning":{"required":null,"chemicals":[],"endpoint":null,"notes":null},"ghs_labeling":{"required":null,"signal_word":null,"pictograms":[],"hazard_statements":[],"notes":null},"hidden_ingredients":{"trade_secret_protected":null,"categories_hidden":[],"estimated_count":null,"known_concerns":null,"notes":null},"notes":null},"recalls":[],"regulatory_gap":null,"notes":null},"lifecycle":{"recyclable":null,"disposal_guidance":"Varies by material; check local recycling guidelines","hazardous_waste":false,"expected_lifespan":"1-3_years"},"formulation":{"form":"liquid","key_ingredients":[{"hq_id":null,"name":"Water (H2O)","role":"base_material","concentration_pct":">99"},{"hq_id":null,"name":"Mineral content (Ca, Mg, Na, K)","role":"additive","concentration_pct":"0.1-0.5"},{"hq_id":null,"name":"Disinfectant residue (chlorine, fluoride)","role":"additive","concentration_pct":"0.5-2"},{"hq_id":null,"name":"Contaminants (trace, varies by location)","role":"additive","concentration_pct":"trace"}],"certifications":[]},"materials":{"common":[{"material_id":"hq-m-env-000023","material_name":"Pharmaceuticals and personal care products in drinking water","component":"Finished drinking water from municipal treatment plants","prevalence":"common"}],"concerning":[{"material_id":"hq-m-env-000023","concern":"Ethinyl estradiol (oral contraceptive) — endocrine disruptor at ng/L aquatic concentrations; feminizes male fish; no federal MCL; unknown human health significance at lifetime low-dose tap water exposure","compounds_of_concern":["hq-c-org-000625"],"source_refs":[]},{"material_id":"hq-m-env-000023","concern":"Metformin — most prevalent pharmaceutical in drinking water (70–80% of US streams); chronic human exposure never risk-assessed; endocrine effects documented in fish","compounds_of_concern":["hq-c-org-000353"],"source_refs":[]},{"material_id":"hq-m-env-000023","concern":"Antibiotics in drinking water (trimethoprim, erythromycin) — select for antibiotic-resistant bacteria in gut microbiota and aquatic ecosystems; sub-therapeutic concentrations drive resistance phenotype development","compounds_of_concern":[],"source_refs":[]},{"material_id":"hq-m-env-000023","concern":"Carbamazepine and fluoxetine — persistent, bioaccumulative, neurotoxic to aquatic organisms at µg/L concentrations; not removed by standard treatment; unknown human neurodevelopmental effects at chronic low exposure","compounds_of_concern":[],"source_refs":[]},{"material_id":"hq-m-env-000023","concern":"Regulatory gap: NO federal MCL for ANY pharmaceutical in US drinking water; EPA CCL (contaminant candidate list) includes some PPCPs but regulatory pathway to MCL is 5–10 years; monitoring NOT mandated for utilities","compounds_of_concern":[],"source_refs":[]},{"material_id":"hq-m-env-000023","concern":"Potential contaminant: Endocrine-active pharmaceutical residues (EE2, ibuprofen, metformin)","compounds_of_concern":["hq-c-org-000027"],"source_refs":[]}],"preferred":[{"material_id":null,"material_name":"Advanced drinking water treatment (reverse osmosis, ozonation, UV, granular activated carbon)","why_preferred":"","tradeoffs":"Effective for >95% PPCP removal; high capital cost ($5M–50M for municipal system retrofit); high operational cost (membrane replacement, energy); produces large waste stream; not widely adopted due to cost; home RO systems affordable but produce waste water 3:1"},{"material_id":null,"material_name":"Pharmaceutical take-back programs (reduce excretion-based contamination)","why_preferred":"","tradeoffs":"Reduces new pharmaceutical loading into wastewater; limited participation (<10% of medications); does not address historical/current PPCP burden in aquatic systems; does not remove PPCPs from treated wastewater"},{"material_id":null,"material_name":"Wastewater treatment optimization (conventional → secondary → advanced PPCP removal)","why_preferred":"","tradeoffs":"Shifts responsibility to wastewater systems; high capital/operational cost; regulatory mandate would be required (not currently mandated)"}]},"compound_composition":[{"hq_id":"hq-c-org-002022","compound_name":"Chlorine dioxide (ClO₂)","role":"base","typical_concentration":null},{"hq_id":"hq-c-org-000353","compound_name":"Metformin","role":"base","typical_concentration":null},{"hq_id":"hq-c-org-000006","compound_name":"Bisphenol A","role":"base","typical_concentration":null},{"hq_id":"hq-c-org-000058","compound_name":"Deoxynivalenol (DON / vomitoxin)","role":"base","typical_concentration":null}],"identifiers":{"common_names":["tap water","drinking water","municipal water supply","pharmaceutical contamination","hormone in water"],"aliases":[],"manufacturer":null,"brands":[]},"brand_examples":[{"brand":"Generic Mass-Market Brand A","manufacturer":"Consumer Products Corporation","market_position":"mass_market","notable":"Widely available mass-market option"},{"brand":"Generic Mass-Market Brand B","manufacturer":"Consumer Goods Ltd","market_position":"mass_market","notable":"Popular budget alternative"},{"brand":"Premium Brand A","manufacturer":"Premium Consumer Inc","market_position":"premium","notable":"Upscale premium positioning"},{"brand":"Professional Brand","manufacturer":"Professional Products Co","market_position":"professional","notable":"Professional/salon-grade option"},{"brand":"Specialty Eco-Brand","manufacturer":"Natural Products Ltd","market_position":"premium","notable":"Sustainable/natural product line"}],"brand_examples_disclaimer":"Representative branded products of this category. Concerning ingredients listed in materials.concerning[] apply to the category, not necessarily to every named brand. Specific formulations vary by SKU and may have changed since this record was written; consult the brand's current ingredient label before drawing brand-level conclusions.","sources":[{"id":"src_001","type":"government","title":"USGS National Pharmaceutical Study in Streams (2002) and Update (2022)","year":2022},{"type":"regulation","title":"Consumer Product Safety Act (CPSA) + FHSA","jurisdiction":"USA","id":"src_5f50aaf4"},{"type":"regulation","title":"EPA Safer Choice / Design for the Environment","jurisdiction":"USA","id":"src_44bbb086"},{"type":"regulation","title":"CLP Regulation (EC) No 1272/2008","jurisdiction":"EU","id":"src_74945c54"},{"id":"fda_metformin_label_2023","type":"regulatory","title":"FDA Prescribing Information: Metformin (Glucophage) — biguanide T2DM; lactic acidosis; renal contraindication eGFR <30; contrast media; B12 deficiency; PCOS off-label; pediatric ≥10yr; cardiovascular outcomes benefit; GI tolerability; hemodialysis (2023)","year":2023,"inherited_from_compound":"hq-c-org-000353"},{"id":"aspca_apcc_cardiac_drugs_2023","type":"veterinary","title":"ASPCA Animal Poison Control Center: Cardiac Drug Toxicosis in Pets — statin myopathy in cats; beta-blocker bradycardia dogs; CCB toxicity (amlodipine/diltiazem); ACE inhibitor renal effects; warfarin anticoagulant; furosemide; toxic dose thresholds (2023)","year":2023,"inherited_from_compound":"hq-c-org-000353"},{"type":"regulatory","citation":"EFSA CEP Panel. Re-evaluation of the risks to public health related to the presence of bisphenol A (BPA) in foodstuffs. EFSA Journal 2023;21(4):6857.","url":"https://efsa.onlinelibrary.wiley.com/doi/10.2903/j.efsa.2023.6857","date":"2023-04-19","id":"efsa_2023","inherited_from_compound":"hq-c-org-000006"},{"type":"regulatory","citation":"ECHA Member State Committee. Identification of BPA as SVHC.","date":"2017-06-16","id":"echa_svhc_2017","inherited_from_compound":"hq-c-org-000006"},{"id":"efsa_don_2017","type":"regulatory","title":"EFSA Panel on Contaminants: Risks to Human and Animal Health from Deoxynivalenol in Food and Feed","year":2017,"inherited_from_compound":"hq-c-org-000058"},{"id":"fda_don_advisory","type":"regulatory","title":"US FDA Advisory Levels for Deoxynivalenol in Finished Wheat Products","year":2010,"inherited_from_compound":"hq-c-org-000058"},{"type":"regulatory","title":"US Environmental Protection Agency (EPA)","jurisdiction":"USA","id":"src_defdd418","extraction":"description_reference"}],"meta":{"schema_version":"4.0.0","last_updated":"2026-03-25","timestamp":"2026-05-14T01:27:04.876Z"}}